Authors: Singh, Neetu¹; Mitra, Amit Kumar¹; Garg, Vivek Kumar²; Agarwal, Amit³; Sharma, Mandira²; Chaturvedi, Rashmi²; Rath, Srikanta Kumar¹

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 16, Number 12, 2007 , pp. 587-597(11)

Publisher: Cognizant Communication Corporation

Abstract:

Cytochrome P-450 (CYP) 1A1 is a candidate gene for low penetrance breast cancer (BC) susceptibility. Evidences demonstrate that ethnic differences in BC incidence may be partly due to genetic factors, including polymorphisms in the genes. In the present case control study four CYP1A1 gene polymorphisms, m1 (T6235C), m2 (A4889G), m3 (T5639C), and m4 (C4887A) were studied for their association with BC conjointly with the known risk factors such as age, menopausal status, diet, and life style. Polymorphisms of CYP1A1 gene were detected by PCR-RFLP method. The homozygous mutant (G/G) of m2 polymorphism was significantly associated with BC. Consequently, association of both m2 heterozygous mutant genotype (A/G) and combined group [homozygous (G/G) plus heterozygous (A/G) mutant genotype] showed association with postmenopausal women. Incidences of BC were also found to be independent of clinicopathological factors except heterozygous mutant genotype (A/G) m2 showed association with dietary factors and high grade tumors while homozygous mutant (G/G) m2 showed association with ER/PR-positive BC cases. Wild-type m3 was observed in all the subjects in cases as well as in controls. No significant association was observed between m1 and m3 polymorphisms and BC risk in all the subjects as well as when stratified into pre- and postmenopausal subjects. This indicates that out of m1 and m2 polymorphisms that have been reported in Asians, only m2 is associated with North Indians.

Keywords: Breast cancer; CYP1A1 polymorphism

Document Type: Research article

Affiliations: 1: Genotoxicity Laboratory, Toxicology Division, Central Drug Research Institute, Lucknow 226 001, Uttar Pradesh, India 2: Lucknow Cancer Institute, Lucknow 226 001, Uttar Pradesh, India 3: Department of Endocrine Surgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGI), Lucknow 226 014, Uttar Pradesh, India

Publication date: 2007-12-01

More about this publication?

• Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
  Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Singh, Neetu ;  Mitra, Amit Kumar ;  Garg, Vivek Kumar ;  Agarwal, Amit ;  Sharma, Mandira ;  Chaturvedi, Rashmi ;  Rath, Srikanta Kumar

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers